Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios

Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case serie...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhtar, Komal, Sravanthi, Metlapalli Venkata, D’Angelo, Josephine, Sivapiragasam, Abirami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421057/
https://www.ncbi.nlm.nih.gov/pubmed/36017984
http://dx.doi.org/10.1177/23247096221121408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421057/
https://www.ncbi.nlm.nih.gov/pubmed/36017984
http://dx.doi.org/10.1177/23247096221121408

Ejemplares similares